 <h1>Diovan Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>valsartan</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about valsartan. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Diovan.</p><h2>In Summary</h2><p><b>Common side effects of Diovan include:</b> dizziness and increased serum potassium. <b>Other side effects include:</b> hypotension.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to valsartan: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule; Tablet; Solution)</p><p>When pregnancy is detected, discontinue valsartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, valsartan (the active ingredient contained in Diovan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking valsartan:</p><p>
<i>Less common</i>
</p><ul>
<li>Bloody urine</li>
<li>cold sweats</li>
<li>confusion</li>
<li>decreased frequency or amount of urine</li>
<li>difficult breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up from a lying position</li>
<li>fainting</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>swelling of the face, fingers, or lower legs</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chills</li>
<li>fever</li>
<li>hoarseness</li>
<li>sore throat</li>
<li>swelling of the mouth, hands, or feet</li>
<li>trouble with swallowing or breathing (sudden)</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Dark urine</li>
<li>general tiredness and weakness</li>
<li>light-colored stools</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of valsartan may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>back pain</li>
<li>blurred vision</li>
<li>cold or flu-like symptoms</li>
<li>coughing</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>headache</li>
<li>muscle pain or stiffness</li>
<li>pain, swelling, or redness in the joints</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss</li>
<li>thinning of the hair</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to valsartan: oral capsule, oral tablet</i></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 14%), dizziness (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Dizziness </p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>A 71-year-old woman experienced an acute onset of angioedema and a photosensitive pruritic rash after 3 months of valsartan (the active ingredient contained in Diovan) therapy.  Her symptoms dissipated and the rash resolved after treatment with subcutaneous epinephrine, intravenous methylprednisolone, diphenhydramine, and emollient cream.</p>
<p></p>
<p>A unique case of dose-dependent, valsartan-induced angioedema has been reported.  Two hours after initiating a dose increase (160 to 320 mg/day) of valsartan, a patient developed angioedema (i.e., swelling of lips and tongue).  Symptoms resolved following a reduction in dose to the original dosage of 160 mg/day.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Angioedema<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Symptomatic hypotension in 5.5% of heart failure patients in clinical trials</p>
<p><b>Rare</b> (less than 0.1%): Palpitations, chest pain</p>
<p><b>Frequency not reported</b>: Dizziness related to orthostatic hypotension</p>
<p><b>Postmarketing reports</b>: Heart failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperkalemia, hyponatremia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Impaired renal function, increases in serum creatinine concentrations, blood urea nitrogen, and potassium</p>
<p><b>Postmarketing reports</b>: Renal failure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Pruritus, rash, alopecia</p>
<p><b>Postmarketing reports</b>: Bullous dermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Uncommon</b> (0.1% to 1%): Diarrhea, constipation, dry mouth, dyspepsia, anorexia, nausea, vomiting, flatulence</p>
<p><b>Postmarketing reports</b>: Taste disturbance (i.e., altered sensitivity of basic tastes) has been reported following repeated dosing<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle cramps, myalgias</p>
<p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety, insomnia, paresthesias, somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very rare</b> (less than 0.01%): Impotence<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hematocrit decreased, hemoglobin decreased, neutropenia</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia, vasculitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Valsartan-associated hepatotoxicity in a patient with hepatitis B surface antigen (HBs-Ag) positivity (without signs and symptoms) has been reported.  After 1 month of treatment with valsartan (the active ingredient contained in Diovan)  this patient developed pruritic erythematous skin changes, nausea, jaundice, right subcostal abdominal pain, elevated liver enzymes, and mild hepatomegaly.  Signs and symptoms of hepatotoxicity resolved within 2 to 3 weeks following discontinuation of valsartan and the patient remained asymptomatic after 6 months of follow-up.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Hepatitis</p>
<p><b>Frequency not reported</b>: Hepatic enzymes increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. McInnes GT "Clinical advantage of valsartan." Cardiology 91 (1999): 14-8</p><p id="ref_3">3. Oparil S, Dyke S, Harris F, et al. "The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension." Clin Ther 18 (1996): 797-810</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_5">5. Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996): 1147-115</p><p id="ref_6">6. Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996): s142-6</p><p id="ref_7">7. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M "Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide." J Clin Pharmacol 37 (1997): 101-7</p><p id="ref_8">8. Irons BK,  Kumar A "Valsartan-induced angioedema." Ann Pharmacother 37 (2003): 1024-7</p><p id="ref_9">9. Frye CB, Pettigrew TJ "Angioedema and photosensitive rash induced by valsartan." Pharmacotherapy 18 (1998): 866-8</p><p id="ref_10">10. Burnier M, Roch-Ramel F, Brunner HR "Renal effects of angiotensin II receptor blockade in normotensive subjects." Kidney Int 49 (1996): 1787-90</p><p id="ref_11">11. Ziai F, Ots M, Provoost AP, Troy JL, Rennke HG, Brenner BM, Mackenzie HS "The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure." Kidney Int Suppl 57 (1996): s132-6</p><p id="ref_12">12. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR "Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects." Hypertension 25 (1995): 602-9</p><p id="ref_13">13. Marquart-Elbaz C,  Grosshans E,  Lipsker D,  Lipsker D "Sartans, angiotensin II receptor antagonists, can induce psoriasis." Br J Dermatol 147 (2002): 617-8</p><p id="ref_14">14. Tsuruoka S,  Wakaumi M,  Ioka T, et al. "Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan." Br J Clin Pharmacol 60 (2005): 204-7</p><p id="ref_15">15. Flores CA,  Ardiles LG,  Aros CA, et al. "Valsartan-Induced Hematocrit Changes in Renal Transplant Patients." Transplant Proc 37 (2005): 1586-1588</p><p id="ref_16">16. Kiykim A,  Altintas E,  Sezgin O, et al. "Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient." Am J Gastroenterol 98 (2003): 507</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Losartan vs Valsartan - What's the difference between them?</li>
<li>What is the strength of Prexxartan (valsartan) oral solution?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Diovan (valsartan)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>62 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: angiotensin receptor blockers</li>
<li>FDA Alerts (9)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Diovan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prexxartan</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Diovan HCT</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Left Ventricular Dysfunction</li>
<li>High Blood Pressure</li>
<li>Heart Attack</li>
<li>Heart Failure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to valsartan: oral capsule, oral tablet</i></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 14%), dizziness (up to 14%)</p><p><b>Common</b> (1% to 10%): Dizziness </p><p><b>Uncommon</b> (0.1% to 1%): Vertigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Cough</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>A 71-year-old woman experienced an acute onset of angioedema and a photosensitive pruritic rash after 3 months of valsartan (the active ingredient contained in Diovan) therapy.  Her symptoms dissipated and the rash resolved after treatment with subcutaneous epinephrine, intravenous methylprednisolone, diphenhydramine, and emollient cream.</p><p></p><p>A unique case of dose-dependent, valsartan-induced angioedema has been reported.  Two hours after initiating a dose increase (160 to 320 mg/day) of valsartan, a patient developed angioedema (i.e., swelling of lips and tongue).  Symptoms resolved following a reduction in dose to the original dosage of 160 mg/day.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Angioedema<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Symptomatic hypotension in 5.5% of heart failure patients in clinical trials</p><p><b>Rare</b> (less than 0.1%): Palpitations, chest pain</p><p><b>Frequency not reported</b>: Dizziness related to orthostatic hypotension</p><p><b>Postmarketing reports</b>: Heart failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperkalemia, hyponatremia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Impaired renal function, increases in serum creatinine concentrations, blood urea nitrogen, and potassium</p><p><b>Postmarketing reports</b>: Renal failure<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Pruritus, rash, alopecia</p><p><b>Postmarketing reports</b>: Bullous dermatitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Uncommon</b> (0.1% to 1%): Diarrhea, constipation, dry mouth, dyspepsia, anorexia, nausea, vomiting, flatulence</p><p><b>Postmarketing reports</b>: Taste disturbance (i.e., altered sensitivity of basic tastes) has been reported following repeated dosing<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle cramps, myalgias</p><p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Anxiety, insomnia, paresthesias, somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very rare</b> (less than 0.01%): Impotence<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hematocrit decreased, hemoglobin decreased, neutropenia</p><p><b>Postmarketing reports</b>: Thrombocytopenia, vasculitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Valsartan-associated hepatotoxicity in a patient with hepatitis B surface antigen (HBs-Ag) positivity (without signs and symptoms) has been reported.  After 1 month of treatment with valsartan (the active ingredient contained in Diovan)  this patient developed pruritic erythematous skin changes, nausea, jaundice, right subcostal abdominal pain, elevated liver enzymes, and mild hepatomegaly.  Signs and symptoms of hepatotoxicity resolved within 2 to 3 weeks following discontinuation of valsartan and the patient remained asymptomatic after 6 months of follow-up.<sup>[Ref]</sup></p><p><b>Very rare</b> (less than 0.01%): Hepatitis</p><p><b>Frequency not reported</b>: Hepatic enzymes increased<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. McInnes GT "Clinical advantage of valsartan." Cardiology 91 (1999): 14-8</p><p id="ref_3">3. Oparil S, Dyke S, Harris F, et al. "The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension." Clin Ther 18 (1996): 797-810</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_5">5. Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996): 1147-115</p><p id="ref_6">6. Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996): s142-6</p><p id="ref_7">7. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M "Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide." J Clin Pharmacol 37 (1997): 101-7</p><p id="ref_8">8. Irons BK,  Kumar A "Valsartan-induced angioedema." Ann Pharmacother 37 (2003): 1024-7</p><p id="ref_9">9. Frye CB, Pettigrew TJ "Angioedema and photosensitive rash induced by valsartan." Pharmacotherapy 18 (1998): 866-8</p><p id="ref_10">10. Burnier M, Roch-Ramel F, Brunner HR "Renal effects of angiotensin II receptor blockade in normotensive subjects." Kidney Int 49 (1996): 1787-90</p><p id="ref_11">11. Ziai F, Ots M, Provoost AP, Troy JL, Rennke HG, Brenner BM, Mackenzie HS "The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure." Kidney Int Suppl 57 (1996): s132-6</p><p id="ref_12">12. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR "Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects." Hypertension 25 (1995): 602-9</p><p id="ref_13">13. Marquart-Elbaz C,  Grosshans E,  Lipsker D,  Lipsker D "Sartans, angiotensin II receptor antagonists, can induce psoriasis." Br J Dermatol 147 (2002): 617-8</p><p id="ref_14">14. Tsuruoka S,  Wakaumi M,  Ioka T, et al. "Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan." Br J Clin Pharmacol 60 (2005): 204-7</p><p id="ref_15">15. Flores CA,  Ardiles LG,  Aros CA, et al. "Valsartan-Induced Hematocrit Changes in Renal Transplant Patients." Transplant Proc 37 (2005): 1586-1588</p><p id="ref_16">16. Kiykim A,  Altintas E,  Sezgin O, et al. "Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient." Am J Gastroenterol 98 (2003): 507</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Losartan vs Valsartan - What's the difference between them?</li>
<li>What is the strength of Prexxartan (valsartan) oral solution?</li>
</ul><h2>More about Diovan (valsartan)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>62 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: angiotensin receptor blockers</li>
<li>FDA Alerts (9)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Diovan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Diovan HCT</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Left Ventricular Dysfunction</li>
<li>High Blood Pressure</li>
<li>Heart Attack</li>
<li>Heart Failure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>